Trials by strength of evidence

Every trial in OnCo ranked by a disclosed evidence-strength score, with its primary endpoint drawn as people out of 100 or as median months. The score measures how much and what kind of evidence exists, not how large the benefit is.

How the score is computed

Phase: 3 → 30 · 2/3 → 22 · 2 → 15 · 1/2 → 8 · 1 → 4 · observational or platform → 10
Size: 5 × log10(enrolled), capped at 20 (100 people → 10, 1,000 → 15, 10,000 → 20)
Primary endpoint: overall survival → 20 · time to progression or recurrence → 14 · surrogate (response, pCR, detection) → 8
Result: positive → 15 · mixed → 6 · ongoing → 0 · negative or withdrawn → −20
Replication: an independent or consistent confirming study → 10
A linked product is approved → 5

Products score from their status tier, their best linked trial, and approvals; technologies and targets from their status and best linked product. Full code in src/lib/evidence.ts.

Primary endpoints as pictures

ARASENS · Metastatic hormone-sensitive prostate cancer

Overall survivalprimary

HR 0.68 (0.57 to 0.8) · p <0.001

Download

Median not reached

	Trial			Primary endpoint
1	ARASENS Metastatic hormone-sensitive prostate cancer: ADT + docetaxel + darolutamide vs ADT + docetaxel	Phase 3	Positive	Overall survival: 48.9 months, HR 0.68	1,306	96	Strong
2	CheckMate 649 First-line HER2-negative advanced gastric/GEJ/oesophageal adenocarcinoma: nivolumab + chemotherapy vs chemotherapy	Phase 3	Positive	Overall survival, PD-L1 CPS ≥5: 14.4 months vs 11.1 months, HR 0.71	1,581	96	Strong
3	IALT (International Adjuvant Lung Cancer Trial) Completely resected non-small-cell lung cancer, any stage I to III: three or four cycles of cisplatin-based chemotherapy versus observation, with overall survival as the primary endpoint	Phase 3	Positive	Overall survival at 5 years: 44.5% vs 40.4%, HR 0.86	1,867	96	Strong
4	KEYNOTE-042 Untreated advanced non-small-cell lung cancer without EGFR or ALK alterations and PD-L1 tumour proportion score of 1 percent or more: pembrolizumab versus platinum doublet chemotherapy	Phase 3	Positive	Overall survival, PD-L1 tumour proportion score 50% or more: 20 months vs 12.2 months, HR 0.69	1,274	96	Strong
5	KEYNOTE-859 First-line HER2-negative advanced gastric/GEJ adenocarcinoma: pembrolizumab + chemotherapy vs placebo + chemotherapy	Phase 3	Positive	Overall survival, all randomised: 12.9 months vs 11.5 months, HR 0.78	1,579	96	Strong
6	AFFIRM Metastatic castration-resistant prostate cancer after docetaxel, stratified by ECOG performance status and pain intensity: enzalutamide 160 mg daily against placebo, randomised 2:1, with overall survival as the primary endpoint	Phase 3	Positive	Overall survival (median): 18.4 months vs 13.6 months, HR 0.63	1,199	95	Strong
7	ANITA (Adjuvant Navelbine International Trialist Association) Completely resected stage IB to IIIA non-small-cell lung cancer: vinorelbine 30 mg/m2 with cisplatin 100 mg/m2 versus observation, with overall survival as the primary endpoint	Phase 3	Positive	Overall survival (median): 65.7 months vs 43.7 months, HR 0.8	840	95	Strong
8	CASPIAN First-line extensive-stage SCLC: platinum-etoposide + durvalumab (± tremelimumab) vs platinum-etoposide	Phase 3	Positive	Overall survival: 13 months vs 10.3 months, HR 0.73	805	95	Strong
9	CheckMate 214 Untreated advanced clear-cell RCC: nivolumab + ipilimumab vs sunitinib	Phase 3	Positive	Overall survival, intermediate/poor risk (8-year follow-up): pending	1,096	95	Strong
10	CheckMate 648 First-line advanced oesophageal squamous cell carcinoma: nivolumab + chemotherapy, or nivolumab + ipilimumab (chemotherapy-free), vs chemotherapy	Phase 3	Positive	Overall survival, PD-L1 ≥1% (nivolumab + chemotherapy): 15.4 months vs 9.1 months, HR 0.54	970	95	Strong
11	COU-AA-301 Metastatic castration-resistant prostate cancer after docetaxel: prednisone 5 mg twice daily for everyone, with abiraterone acetate 1000 mg daily or placebo, randomised 2:1, with overall survival as the primary endpoint	Phase 3	Positive	Overall survival (median): 14.8 months vs 10.9 months, HR 0.65	1,195	95	Strong
12	HIMALAYA First-line unresectable HCC: STRIDE (single priming dose tremelimumab + durvalumab) vs sorafenib	Phase 3	Positive	Overall survival: 16.4 months vs 13.8 months, HR 0.78	1,171	95	Strong
13	KEYNOTE-006 Advanced melanoma, ≤1 prior systemic therapy: pembrolizumab (two schedules) vs ipilimumab	Phase 3	Positive	Overall survival at 10 years: 34% vs 23.6%	834	95	Strong
14	KEYNOTE-024 & KEYNOTE-189 First-line metastatic NSCLC without EGFR/ALK: pembrolizumab alone (PD-L1 TPS ≥50%, KEYNOTE-024) or pembrolizumab + platinum-pemetrexed (any PD-L1, non-squamous, KEYNOTE-189)	Phase 3	Positive	KEYNOTE-024: overall survival at 5 years, PD-L1 ≥50%: 31.9% vs 16.3%, HR 0.62	921	95	Strong
15	KEYNOTE-048 Untreated recurrent or metastatic HNSCC: pembrolizumab alone, pembrolizumab + platinum/5-FU, or cetuximab + platinum/5-FU (EXTREME)	Phase 3	Positive	Overall survival, CPS ≥20, pembrolizumab monotherapy: 14.9 months vs 10.7 months, HR 0.61	882	95	Strong
16	KEYNOTE-355 First-line metastatic TNBC: pembrolizumab + chemotherapy vs chemotherapy	Phase 3	Positive	Overall survival, PD-L1 CPS ≥10: 23 months vs 16.1 months, HR 0.73	882	95	Strong
17	KEYNOTE-426 Untreated advanced clear-cell RCC: pembrolizumab + axitinib vs sunitinib	Phase 3	Positive	Overall survival (final, 5-year): 47.2 months vs 40.8 months, HR 0.84	861	95	Strong
18	KEYNOTE-966 First-line advanced biliary tract cancer: gemcitabine-cisplatin + pembrolizumab vs + placebo	Phase 3	Positive	Overall survival: 12.7 months vs 10.9 months, HR 0.83	1,069	95	Strong
19	LATITUDE High-risk de novo metastatic hormone-sensitive prostate cancer: ADT + abiraterone vs ADT	Phase 3	Positive	Overall survival: 53.3 months vs 36.5 months, HR 0.66	1,209	95	Strong
20	OAK Squamous or non-squamous non-small-cell lung cancer after one or two previous cytotoxic regimens including a platinum doublet: atezolizumab 1200 mg versus docetaxel 75 mg/m2, both every three weeks, with co-primary overall survival endpoints in the intention-to-treat and PD-L1-expressing populations	Phase 3	Positive	Overall survival (intention to treat): 13.8 months vs 9.6 months, HR 0.73	1,225	95	Strong
21	PARADIGM First-line RAS wild-type metastatic colorectal cancer: panitumumab + mFOLFOX6 vs bevacizumab + mFOLFOX6	Phase 3	Positive	Overall survival, left-sided: 37.9 months vs 34.3 months, HR 0.82	823	95	Strong
22	PEACE-1 De novo metastatic hormone-sensitive prostate cancer: ADT + docetaxel ± abiraterone ± prostate radiotherapy (2×2 factorial)	Phase 3	Positive	Overall survival, abiraterone vs no abiraterone (with ADT + docetaxel): 66 months vs 52 months, HR 0.75	1,173	95	Strong
23	PRIME Previously untreated metastatic colorectal cancer: FOLFOX4 with or without panitumumab, analysed by extended RAS status	Phase 3	Positive	Overall survival (RAS wild-type): 26 months vs 20.2 months, HR 0.78	1,183	95	Strong
24	PROSELICA Metastatic castration-resistant prostate cancer after docetaxel: cabazitaxel 20 mg/m2 against 25 mg/m2, with a non-inferiority design requiring the lower dose to keep at least half the survival benefit cabazitaxel showed against mitoxantrone in TROPIC	Phase 3	Positive	Overall survival (median): 13.4 months vs 14.5 months, HR 1.024	1,200	95	Strong
25	RECOURSE Refractory metastatic colorectal cancer after all standard chemotherapies: trifluridine/tipiracil against placebo	Phase 3	Positive	Overall survival: 7.1 months vs 5.3 months, HR 0.68	800	95	Strong
26	TAX 327 Metastatic hormone-refractory prostate cancer: prednisone 5 mg twice daily for everyone, with mitoxantrone 12 mg/m2 every three weeks, docetaxel 75 mg/m2 every three weeks, or docetaxel 30 mg/m2 weekly for five of every six weeks, with overall survival as the primary endpoint	Phase 3	Positive	Overall survival (median): 18.9 months vs 17.4 months vs 16.5 months, HR 0.76	1,006	95	Strong
27	VELOUR Metastatic colorectal cancer after an oxaliplatin-based regimen: FOLFIRI with ziv-aflibercept or placebo	Phase 3	Positive	Overall survival: 13.5 months vs 12.06 months, HR 0.817	1,226	95	Strong
28	VISION PSMA+ metastatic castration-resistant prostate cancer after ARPI and taxane: 177Lu-PSMA-617 + SOC vs SOC	Phase 3	Positive	Overall survival: 15.3 months vs 11.3 months, HR 0.62	861	95	Strong
29	ASTRUM-005 First-line ES-SCLC: serplulimab + carboplatin-etoposide vs placebo + carboplatin-etoposide	Phase 3	Positive	Overall survival: 15.4 months vs 10.9 months, HR 0.63	585	94	Strong
30	BEACON CRC BRAF V600E-mutant metastatic colorectal cancer after one or two prior lines: encorafenib plus cetuximab with or without binimetinib, versus irinotecan-based chemotherapy plus cetuximab	Phase 3	Positive	Overall survival (updated analysis): 9.3 months vs 9.3 months vs 5.9 months	665	94	Strong

Trials by strength of evidence

Primary endpoints as pictures

All trials by evidence strength

Trials by strength of evidence

Primary endpoints as pictures

All trials by evidence strength